N-Linked Hydroxamic Acid Derivatives Useful As Antibacterial Agents
AssigneePfizer Inc.
InventorsMatthew Frank Brown, Ye Che, Anthony Marfat, Michael Joseph Melnick, Justin Ian Montgomery, Usa Reilly
Life of this patent
Estimating the term…
Abstract
The present invention is directed to a new class of hydroxamic acid derivatives of formula I, wherein the variables G, T, D, L, R1, R2, R3 are as described herein, their use as LpxC inhibitors, and more specifically their use to treat bacterial infections in a patient in need thereof.
Claims16
A compound of the formula:
- or a pharmaceutically acceptable salt thereof,
- wherein
- R1 is C1-C3 alkyl;
- R2 is hydrogen or C1-C3 alkyl;
- R3 is hydrogen, halogen, C1-C3alkyl, C1-C3alkoxy, trifluoromethyl, or trifluoromethoxy;
- L is absent, or is selected from the group consisting of C1-C6 alkylene which may be optionally substituted, C2-C6 alkenylene, C2-C6 alkynylene, —(CH2)p—O—(CH2)n, and —(CH2)p—O—(CH2)z—O—(CH2)n—;
- n is an integer ranging from 0 to 4;
- p is an integer ranging from 0 to 4;
- q is an integer ranging from 0 to 6
- z is an integer ranging from 1 to 4;
- D is selected from the group consisting of:
- i) (C3-C10)cycloalkyl, optionally substituted,
- ii) (C6-C10)aryl, optionally substituted,
- iii) heteroaryl, optionally substituted,
- iv) heterocyclic, optionally substituted,
- T is absent, or is —S(CH2)z—O—(CH2)n, —O—(CH2)z—S—(CH2)n, —(CH2)q—, —(CH2)n—C(O)—(CH2)p—, —(CH2)n—O—(CH2)p—, —(CH2)n—S—(CH2)p, S—C1-C6 alkylene which may be optionally substituted, —O—C1-C6 alkylene which may be optionally substituted, —O—(CH2)p—C(O)—(CH2)n—, —(CH2)p—C(O)—(CH2)q—O—(CH2)n—, —O—(CH2), —O—(CH2)n—, —O—(CH2)z—O—(CH2)z—O—(CH2)n—, —S—(CH2)z—S—(CH2)n—, —(CH2)n—SH, or —(CH2)n—OH, and;
- G is absent, or is selected from the group consisting of:
- i) (C3-C10)cycloalkyl, optionally substituted;
- ii) (C6-C10)aryl optionally substituted;
- iii) heteroaryl, optionally substituted, and;
- iv) heterocyclic, optionally substituted.
(2R)—N-hydroxy-2-methyl-2-(methylsulfonyl)-4-[2-oxo-4-(2,3,4-trifluorophenyl)pyridin-1(2H)-yl]butanamide, or a pharmaceutically acceptable salt thereof.
(2R)-4-[4-(4-chloro-2,3-difluorophenyl)-2-oxopyridin-1(2H)-yl]-N-hydroxy-2-methyl-2-(methylsulfonyl)butanamide, or a pharmaceutically acceptable salt thereof.
(R)-4-(4-(2-fluoro-4-methoxyphenyl)-2-oxopyridin-1(2H)-yl)-N-hydroxy-2-methyl-2-(methylsulfonyl)butanamide, or a pharmaceutically acceptable salt thereof.
(2R)—N-hydroxy-4-[4-{4-[(trans-4-hydroxycyclohexyl)methoxy]phenyl}-2-oxopyridin-1(2H)-yl]-2-methyl-2-(methylsulfonyl)butanamide, or a pharmaceutically acceptable salt thereof.
(2R)—N-hydroxy-2-methyl-2-(methylsulfonyl)-4-{2-oxo-4-[4-(2H-1,2,3-triazol-2-yl)phenyl]pyridin-1(2H)-yl}butanamide, or a pharmaceutically acceptable salt thereof.
(canceled)
Dependencies are inferred from the claim text.